Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors

References

Page 1

	Year	Citations
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. David W. Rusnak, Karen Lackey, Karen Affleck, PubMed PathologyCell ProliferationCell GrowthTumor BiologyOncology	2001	737
Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity Hwei‐Ru Tsou, Elsebe G. Overbeek-Klumpers, William Hallett, Journal of Medicinal Chemistry Medicinal ChemistryBiochemistrySafer Cyclization StepMedicineNatural Sciences	2005	294
Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2) Allan Wissner, Elsebe Overbeek, Marvin F. Reich, Journal of Medicinal Chemistry Combinatorial ChemistryPharmaceutical ScienceBioorganic ChemistryPharmacotherapy6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles	2002	262
Mechanism of the Stille Reaction. 1. The Transmetalation Step. Coupling of R<sup>1</sup>I and R<sup>2</sup>SnBu<sub>3</sub> Catalyzed by <i>trans</i>-[PdR<sup>1</sup>IL<sub>2</sub>] (R<sup>1</sup> = C<sub>6</sub>Cl<sub>2</sub>F<sub>3</sub>; R<sup>2</sup> = Vinyl, 4-Methoxyphenyl; L = AsPh<sub>3</sub>) Arturo L. Casado, Pablo Espinet Journal of the American Chemical Society Stille ReactionCross-coupling ReactionEngineeringAccepted MechanismNatural Sciences	1998	221
Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-<i>d</i>]pyrimidines Peter Traxler, Guido Bold, Joerg Frei, Journal of Medicinal Chemistry Egf-r Tyrosine KinasePharmacotherapySystem PharmacologyPharmaceutical ChemistryPharmacodynamic Modeling	1997	205
Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series Kimberly G. Petrov, Yuemei Zhang, Malcolm Carter, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryDrug TargetBiochemistryNatural SciencesMedicine	2006	162
Tyrosine Kinase Inhibitors. 11. Soluble Analogues of Pyrrolo- and Pyrazoloquinazolines as Epidermal Growth Factor Receptor Inhibitors: Synthesis, Biological Evaluation, and Modeling of the Mode of Binding Brian D. Palmer, Susanne Trumpp-Kallmeyer, David W. Fry, Journal of Medicinal Chemistry	1997	114
Identification, Characterization and Initial Hit-to-Lead Optimization of a Series of 4-Arylamino-3-Pyridinecarbonitrile as Protein Kinase C theta (PKCθ) Inhibitors Derek C. Cole, Magda Asselin, Agnes Brennan, Journal of Medicinal Chemistry Tcr Signal TransductionDrug TargetInflammatory Lung DiseasePharmacotherapyChemical Biology	2008	45
Protein tyrosine kinase inhibitors as anticancer agents Claudiu T. Supuran, Andrea Scozzafava Expert Opinion on Therapeutic Patents Tumor BiologyMedicinal ChemistrySignal Transduction PathwaysSignal TransductionSignaling Pathway	2004	36
Synthesis and Biological Evaluation of Pyrimidine-Based Dual Inhibitors of Human Epidermal Growth Factor Receptor 1 (HER-1) and HER-2 Tyrosine Kinases Mi Young, Kwang‐Ok Lee, Seok-Jong Kang, Journal of Medicinal Chemistry	2012	33

Page 1